As shown in Table 4, HCCs with S100P expression and p53 mutation had the highest frequencies of high-stage tumor (stage II and III) and ETR (88% and 69% of cases, respectively), which were approximately 2-fold higher than the rates of high-stage tumor and ETR in HCC cases without either S100P expression or the p53 mutation (44% and 35%; P = 1×10−6 and P = 0.00068; respectively). This evidence concerns the gene S100P and hepatocellular carcinoma.